Braveheart Bio (NASDAQ:BRVE) Sets New 12-Month Low – Should You Sell?

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE) hit a new 52-week low during trading on Monday. The stock traded as low as $20.00 and last traded at $20.5740, with a volume of 18803 shares. The stock had previously closed at $20.62.

Analyst Ratings Changes

BRVE has been the subject of several research reports. Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a research report on Tuesday, September 1st. The Goldman Sachs Group began coverage on Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $48.00 target price on the stock. TD Cowen initiated coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating for the company. Wall Street Zen upgraded Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Finally, Stifel Nicolaus assumed coverage on Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $45.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $45.25.

Braveheart Bio Price Performance

Braveheart Bio (NASDAQ:BRVE) last posted its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). On average, analysts anticipate that Braveheart Bio, Inc. will post -1.48 earnings per share for the current year.

Insider Buying and Selling

In other Braveheart Bio news, Director David Lubner purchased 55,555 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $999,990.00. Following the completion of the transaction, the director owned 55,555 shares in the company, valued at approximately $999,990. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Erez Chimovits purchased 1,940,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the purchase, the director owned 11,901,826 shares of the company’s stock, valued at $214,232,868. This trade represents a 19.47% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 8,751,942 shares of company stock valued at $157,534,956 in the last quarter.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.